Catalent (NYSE:CTLT) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a report released on Saturday. The firm set a “sell” rating on the stock.

CTLT has been the topic of several other reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, February 20th. Barclays lifted their price target on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. Stephens reiterated an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. Finally, UBS Group reiterated a “neutral” rating and set a $63.50 price target (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Catalent currently has an average rating of “Hold” and an average target price of $52.46.

Catalent Stock Up 0.2 %

Shares of Catalent stock opened at $55.92 on Friday. The business’s fifty day moving average price is $56.73 and its two-hundred day moving average price is $48.58. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The company has a market capitalization of $10.12 billion, a P/E ratio of -8.22, a PEG ratio of 6.04 and a beta of 1.20. Catalent has a 1-year low of $31.45 and a 1-year high of $60.20.

Catalent (NYSE:CTLT) last announced its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm earned $0.62 EPS. The firm’s revenue was down 10.2% on a year-over-year basis. As a group, research analysts forecast that Catalent will post 0.28 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Thompson Siegel & Walmsley LLC grew its holdings in shares of Catalent by 46.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company’s stock valued at $32,069,000 after buying an additional 223,944 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Catalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after buying an additional 365,648 shares in the last quarter. Tran Capital Management L.P. grew its holdings in shares of Catalent by 12.2% during the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock valued at $16,258,000 after buying an additional 39,208 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of Catalent by 43.1% during the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company’s stock valued at $8,803,000 after buying an additional 58,240 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Catalent by 240.0% during the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock valued at $1,808,000 after purchasing an additional 28,410 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.